Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Reference for batch-sheet asset CNTX-4975 (Centrexion's lead, FDA Fast Track, Phase 3 VICTORY-3 in knee OA pain)—not part of the 2019 Lilly license per primary…
Total deal potential ~$997M including sales milestones; Centrexion CEO Jeffrey Kindler positioned the deal as validation of Centrexion's ability to 'identify…
Reinforced that Lilly's 2019 Centrexion license was for CNTX-0290 (not CNTX-4975); deal extends Lilly's pain portfolio after tanezumab regulatory setbacks and…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Lilly licensed exclusive worldwide rights to CNTX-0290, a Phase 1 small molecule SSTR4 agonist for chronic pain, from Centrexion Therapeutics. Upfront $47.5M, up to $575M in development/regulatory milestones, up to $375M in sales milestones, plus tiered high-single to low-double digit royalties. Optional U.S. co-promotion election.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Centrexion Therapeutics Corporation (this deal) | 2019 | $575M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2019 deals · Eli Lilly and Company deals · Other deals